» Articles » PMID: 32050722

Nucleoside Diphosphate Kinase B Contributes to Arrhythmogenesis in Human-Induced Pluripotent Stem Cell-Derived Cardiomyocytes from a Patient with Arrhythmogenic Right Ventricular Cardiomyopathy

Abstract

Background: Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare, inheritable cardiac disorder characterized by ventricular tachyarrhythmias, progressive loss of cardiomyocytes with fibrofatty replacement and sudden cardiac death. The exact underlying mechanisms are unclear.

Methods: This study investigated the possible roles of nucleoside diphosphate kinase B (NDPK-B) and SK4 channels in the arrhythmogenesis of ARVC by using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).

Results: In hiPSC-CMs from a patient with ARVC, the expression levels of NDPK-B and SK4 channels were upregulated, the cell automaticity was increased and the occurrence rate of arrhythmic events was enhanced. Recombinant NDPK-B applied into hiPSC-CMs from either healthy donors or the patient enhanced SK4 channel current (I), cell automaticity and the occurrence of arrhythmic events, whereas protein histidine phosphatase 1 (PHP-1), a counter actor of NDPK-B, prevented the NDPK-B effect. Application of PHP-1 alone or a SK4 channel blocker also reduced cell automaticity and arrhythmic events.

Conclusion: This study demonstrated that the elevated NDPK-B expression, via activating SK4 channels, contributes to arrhythmogenesis in ARVC, and hence, NDPK-B may be a potential therapeutic target for treating arrhythmias in patients with ARVC.

Citing Articles

The Role of Human-Induced Pluripotent Stem Cells in Studying Cardiac Channelopathies.

Begovic M, Schneider L, Zhou X, Hamdani N, Akin I, El-Battrawy I Int J Mol Sci. 2024; 25(22).

PMID: 39596103 PMC: 11593457. DOI: 10.3390/ijms252212034.


Using induced pluripotent stem cells for drug discovery in arrhythmias.

Teles D, Fine B Expert Opin Drug Discov. 2024; 19(7):827-840.

PMID: 38825838 PMC: 11227103. DOI: 10.1080/17460441.2024.2360420.


Understanding Arrhythmogenic Cardiomyopathy: Advances through the Use of Human Pluripotent Stem Cell Models.

Chua C, Morrissette-McAlmon J, Tung L, Boheler K Genes (Basel). 2023; 14(10).

PMID: 37895213 PMC: 10606441. DOI: 10.3390/genes14101864.


Arrhythmogenic Cardiomyopathy: from Preclinical Models to Genotype-phenotype Correlation and Pathophysiology.

Fan X, Yang G, Duru F, Grilli M, Akin I, Zhou X Stem Cell Rev Rep. 2023; 19(8):2683-2708.

PMID: 37731079 PMC: 10661732. DOI: 10.1007/s12015-023-10615-0.


KCa3.1 Promotes Proinflammatory Exosome Secretion by Activating AKT/Rab27a in Atrial Myocytes during Rapid Pacing.

Liu D, Chen H, Fu Y, Yao Y, He S, Wang Y Cardiovasc Ther. 2023; 2023:3939360.

PMID: 37035755 PMC: 10079387. DOI: 10.1155/2023/3939360.


References
1.
Wieland T, Hippe H, Ludwig K, Zhou X, Korth M, Klumpp S . Reversible histidine phosphorylation in mammalian cells: a teeter-totter formed by nucleoside diphosphate kinase and protein histidine phosphatase 1. Methods Enzymol. 2010; 471:379-402. DOI: 10.1016/S0076-6879(10)71020-X. View

2.
Wieland T . Interaction of nucleoside diphosphate kinase B with heterotrimeric G protein betagamma dimers: consequences on G protein activation and stability. Naunyn Schmiedebergs Arch Pharmacol. 2007; 374(5-6):373-83. DOI: 10.1007/s00210-006-0126-6. View

3.
Marcus F, Edson S, Towbin J . Genetics of arrhythmogenic right ventricular cardiomyopathy: a practical guide for physicians. J Am Coll Cardiol. 2013; 61(19):1945-8. DOI: 10.1016/j.jacc.2013.01.073. View

4.
Srivastava S, Panda S, Li Z, Fuhs S, Hunter T, Thiele D . Histidine phosphorylation relieves copper inhibition in the mammalian potassium channel KCa3.1. Elife. 2016; 5. PMC: 5005030. DOI: 10.7554/eLife.16093. View

5.
Akdis D, Brunckhorst C, Duru F, Saguner A . Arrhythmogenic Cardiomyopathy: Electrical and Structural Phenotypes. Arrhythm Electrophysiol Rev. 2016; 5(2):90-101. PMC: 5013177. DOI: 10.15420/AER.2016.4.3. View